Lilly Q2: Mounjaro $9.94B, Zepbound $4.93B

Eli Lilly’s second-quarter report turned into a single-company snapshot of how large the GLP-1 market has become. On August 5, Lilly said revenue rose 48% to $22.97 billion in the quarter, led primarily by volume growth for Mounjaro and Zepbound, its tirzepatide medicines for diabetes and obesity. (investor.lilly.com) The two products did more than carry the quarter. Mounjaro generated $9.94 billion in sales and Zepbound generated $4.93 billion, putting the combined total at roughly $14.87 billion — about 65% of Lilly’s quarterly revenue. (investor.lilly.com 1) (investor.lilly.com 2) Lilly also raised its full-year 2026 revenue guidance to $85 billion to $87 billion, up from $82 billion to $85 billion previously, as Chief Executive David Ricks said the company had delivered 48% revenue growth and was “building for the future.” ### How big were Mounjaro and Zepbound inside the quarter? (investor.lilly.com) Mounjaro’s $9.94 billion made it Lilly’s largest single product in the quarter, while Zepbound’s $4.93 billion established obesity treatment as one of the company’s biggest businesses on its own. The two drugs together contributed nearly two-thirds of total second-quarter revenue. (investor.lilly.com) That concentration matters because Lilly’s overall revenue base is now moving in step with demand for tirzepatide. The company said second-quarter growth was driven primarily by Mounjaro and Zepbound volume. (investor.lilly.com) ### What does the Mounjaro number show? Mounjaro sales rose 91% from a year earlier to $9.94 billion, according to Lilly’s second-quarter disclosure. The drug is approved for type 2 diabetes, but its scale also reflects how central tirzepatide has become to Lilly’s commercial growth. The quarter’s product mix shows that Lilly is drawing growth from both diabetes and obesity treatment. (investor.lilly.com) Zepbound, the obesity brand for tirzepatide, added another $4.93 billion in quarterly sales. ### Why did Lilly still talk about earnings charges? Second-quarter reported earnings per share rose 26% to $7.94, while non-GAAP earnings per share rose 33% to $8.38, Lilly said. (investor.lilly.com) The company also said both figures included $3.03 per share of acquired in-process research and development charges, compared with $0.14 in the year-earlier quarter. (investor.lilly.com) David Ricks said Lilly was “building for the future,” and the company tied that to business-development activity, new manufacturing commitments in Indiana and pipeline work including retatrutide. (investor.lilly.com) ### What else did Lilly update alongside the sales figures? Lilly said it completed several acquisitions in the quarter and, after quarter end, completed three more deals to build an infectious disease portfolio and entered an agreement to acquire AtaiBeckley. The company also said it committed an additional $4.5 billion to expand Indiana manufacturing sites. (investor.lilly.com) In the pipeline, Lilly said positive Phase 3 data from three more retatrutide obesity trials completed the clinical package for global registrations in obesity, obstructive sleep apnea and knee osteoarthritis pain. The company said it plans to submit a Biologics License Application to the U.S. (investor.lilly.com) Food and Drug Administration in the first quarter of 2027. ### When is the next checkpoint? Lilly’s investor calendar lists its third-quarter 2026 earnings call for October 29 at 10:00 a.m. EDT. Between now and then, investors will be watching whether Mounjaro and Zepbound remain the main drivers of the company’s updated $85 billion to $87 billion revenue outlook. (investor.lilly.com) (investor.lilly.com)